Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
HIP1
REST API REST API
Homo sapiens
HIP1 is differentially expressed in 304 experiments: 128 organism parts: kidney, lung, ... (126 more);, 194 disease states: normal, control, ... (192 more);, 95 cell types 439 cell lines 44 compound treatments and 76 other conditions.
Synonyms ILWEQ
Orthologs Q69HP0_CIOIN (Ciona intestinalis)   HIP1 (Bos taurus)   Hip1 (Mus musculus)   HIP1 (Gallus gallus)   SLA2 (Saccharomyces cerevisiae)   Hip1 (Rattus norvegicus)   hip1 (Danio rerio)   Hip1 (Drosophila melanogaster)   hip1 (Xenopus laevis)   HIP1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term endomembrane system, phosphatidylinositol binding, protein binding, apoptosis, regulation of transcription, DNA-dependent, cytoskeleton, cytoplasm, clathrin coat assembly, membrane, clathrin-coated vesicle, Golgi apparatus, clathrin binding, activation of caspase activity, clathrin coated vesicle membrane, phospholipid binding, membrane fraction, intracellular membrane-bounded organelle, cell differentiation, induction of apoptosis, nucleus, cell death, cytoplasmic vesicle, structural constituent of cytoskeleton, binding, regulation of apoptosis, actin binding, endocytosis, positive regulation of receptor-mediated endocytosis
InterPro Term ANTH, ILWEQ, Epsin-like_N, Epsin_dom_N
UniProt Accession Q8TDA4, B4DYD7, O00291, C9JMG5, B4DK46, E7ES17
Gene-Disease Assocation PROSTATE CANCER
Search EB-eye ENSG00000127946
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (44 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
AGS
2
E-MTAB-37, E-GEOD-15460
BT20
2
E-MTAB-37, E-MTAB-62
HT1080
2
E-MTAB-37, E-GEOD-20089
KG1
2
E-MTAB-37, E-GEOD-24147
433 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-22529, E-GEOD-22373, E-GEOD-21668, E-MEXP-66, ... (45 experiments)

Factor Value U/D Experiments
cardiac myocyte
2
E-AFMX-5, E-TABM-145
2
2
E-TABM-145, E-TABM-130
stromal cell
1
2
E-MEXP-2034, E-GEOD-1460, E-GEOD-3998
primary fibroblast
1
E-MEXP-66
nucleus pulposus
1
E-MEXP-2488
adipocyte
1
E-MTAB-25
89 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-TABM-15, E-GEOD-16363, ... (58 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-4290
benign prostatic hyperplasia
2
E-MEXP-2034, E-GEOD-7307
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
malignant melanoma
2
E-GEOD-3189, E-MTAB-62
188 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-MEXP-1958, ... (28 experiments)

Factor Value U/D Experiments
none
3
7
E-TABM-782, E-MEXP-1958, E-GEOD-412, E-GEOD-2803, E-GEOD-5824, ... (10 experiments)
R-(-)-apomorphine HCl
1
E-GEOD-995
rapamycin
1
E-GEOD-5824
Ethanol
1
E-MEXP-2417
unknown
1
E-GEOD-7307
untreated
1
E-GEOD-15389
38 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
52 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-22513, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-2666, E-GEOD-4667, E-MEXP-2283 ... (5 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-1751, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-GEOD-2292, E-TABM-321, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-MEXP-2657, E-GEOD-12773, E-TABM-127, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (39 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-13818, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-22541, E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.329 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM